NCT03590171 2026-03-17
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Charite University, Berlin, Germany
Phase 2 Recruiting
Clinical Trials
10 trialsNCT03136146 2026-02-17
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06648889 2026-01-15
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Goethe University
Phase 2 Recruiting
NCT05848687 2026-01-13
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Phase 1/2 Recruiting
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT06034561 2025-05-16
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT03643276 2025-04-06
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
University Hospital Schleswig-Holstein
Phase 3 Recruiting
NCT04996160 2025-01-24
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
Stanford University
Phase 1 Recruiting
NCT04626791 2024-03-12
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT03697356 2023-10-06
Ballondor
Kosin University Gospel Hospital
Phase 2 Recruiting